| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 48 | 2023 | 767 | 13.660 |
Why?
|
| Hematologic Neoplasms | 48 | 2024 | 1870 | 11.470 |
Why?
|
| Dendritic Cells | 46 | 2024 | 1085 | 9.030 |
Why?
|
| Leukemia, Myeloid, Acute | 128 | 2024 | 6915 | 8.110 |
Why?
|
| Primary Myelofibrosis | 30 | 2023 | 831 | 6.300 |
Why?
|
| Social Media | 14 | 2021 | 203 | 5.630 |
Why?
|
| Skin Neoplasms | 23 | 2024 | 4654 | 4.010 |
Why?
|
| Recombinant Fusion Proteins | 13 | 2024 | 1555 | 3.960 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 21 | 2024 | 106 | 3.780 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 38 | 2024 | 923 | 3.680 |
Why?
|
| Antineoplastic Agents | 52 | 2023 | 14289 | 3.390 |
Why?
|
| Myelodysplastic Syndromes | 28 | 2024 | 2979 | 3.210 |
Why?
|
| Sulfonamides | 40 | 2024 | 1823 | 3.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 87 | 2024 | 15862 | 2.620 |
Why?
|
| Polycythemia Vera | 9 | 2024 | 238 | 2.500 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 26 | 2023 | 2527 | 2.300 |
Why?
|
| Protein Kinase Inhibitors | 32 | 2023 | 4757 | 2.180 |
Why?
|
| Humans | 331 | 2024 | 261506 | 2.110 |
Why?
|
| Janus Kinase 2 | 17 | 2023 | 679 | 2.090 |
Why?
|
| Janus Kinase Inhibitors | 5 | 2023 | 63 | 2.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 16 | 2022 | 801 | 1.990 |
Why?
|
| Leukemia, Promyelocytic, Acute | 7 | 2021 | 430 | 1.980 |
Why?
|
| Congresses as Topic | 5 | 2021 | 298 | 1.890 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 12 | 2023 | 426 | 1.830 |
Why?
|
| Bone Marrow | 28 | 2023 | 2358 | 1.810 |
Why?
|
| Cytarabine | 30 | 2023 | 1973 | 1.790 |
Why?
|
| Azacitidine | 23 | 2024 | 1149 | 1.730 |
Why?
|
| Leukemia, Myeloid | 6 | 2019 | 941 | 1.650 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 14 | 2023 | 2390 | 1.630 |
Why?
|
| Nitriles | 19 | 2023 | 906 | 1.560 |
Why?
|
| Aged | 149 | 2024 | 70117 | 1.460 |
Why?
|
| Acute Disease | 14 | 2023 | 2422 | 1.390 |
Why?
|
| Mutation | 55 | 2023 | 15179 | 1.390 |
Why?
|
| Rare Diseases | 5 | 2019 | 351 | 1.380 |
Why?
|
| Hematology | 4 | 2022 | 104 | 1.380 |
Why?
|
| Pyrazoles | 15 | 2022 | 1471 | 1.320 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 18 | 2024 | 2796 | 1.310 |
Why?
|
| Dioxygenases | 7 | 2023 | 159 | 1.310 |
Why?
|
| Molecular Targeted Therapy | 12 | 2022 | 2330 | 1.310 |
Why?
|
| Idarubicin | 13 | 2023 | 446 | 1.290 |
Why?
|
| Remission Induction | 31 | 2023 | 3569 | 1.250 |
Why?
|
| Adult | 125 | 2024 | 77950 | 1.240 |
Why?
|
| Middle Aged | 145 | 2024 | 86204 | 1.240 |
Why?
|
| Philadelphia Chromosome | 13 | 2023 | 793 | 1.190 |
Why?
|
| Aged, 80 and over | 86 | 2023 | 29902 | 1.150 |
Why?
|
| Treatment Outcome | 83 | 2023 | 32848 | 1.140 |
Why?
|
| Male | 159 | 2024 | 123000 | 1.140 |
Why?
|
| Thrombocythemia, Essential | 4 | 2022 | 162 | 1.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 17 | 2023 | 6550 | 1.130 |
Why?
|
| Pyrimidines | 21 | 2023 | 3518 | 1.090 |
Why?
|
| Antimetabolites, Antineoplastic | 10 | 2019 | 1299 | 1.070 |
Why?
|
| Young Adult | 64 | 2023 | 21445 | 0.980 |
Why?
|
| Scholarly Communication | 2 | 2021 | 19 | 0.970 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 10 | 2024 | 1493 | 0.960 |
Why?
|
| Female | 147 | 2024 | 141928 | 0.940 |
Why?
|
| Neoplasms, Second Primary | 5 | 2020 | 1350 | 0.910 |
Why?
|
| Disease Susceptibility | 3 | 2020 | 538 | 0.890 |
Why?
|
| Immunoconjugates | 2 | 2024 | 279 | 0.870 |
Why?
|
| Sweet Syndrome | 2 | 2020 | 36 | 0.860 |
Why?
|
| Lymphocytosis | 1 | 2022 | 58 | 0.840 |
Why?
|
| Castleman Disease | 3 | 2020 | 69 | 0.840 |
Why?
|
| Asparaginase | 5 | 2018 | 184 | 0.830 |
Why?
|
| Thrombosis | 3 | 2023 | 781 | 0.810 |
Why?
|
| Leukemia, Biphenotypic, Acute | 2 | 2019 | 52 | 0.800 |
Why?
|
| Prognosis | 48 | 2024 | 21713 | 0.770 |
Why?
|
| Recurrence | 21 | 2024 | 4758 | 0.770 |
Why?
|
| Videoconferencing | 1 | 2021 | 56 | 0.770 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 162 | 0.770 |
Why?
|
| Neoplasms | 14 | 2024 | 15193 | 0.750 |
Why?
|
| Leukemia | 4 | 2022 | 1635 | 0.740 |
Why?
|
| Arsenic | 1 | 2021 | 49 | 0.730 |
Why?
|
| DNA-Binding Proteins | 10 | 2023 | 4821 | 0.720 |
Why?
|
| Gene Rearrangement | 3 | 2023 | 783 | 0.720 |
Why?
|
| Histiocytosis, Sinus | 1 | 2020 | 86 | 0.720 |
Why?
|
| Plesiomonas | 1 | 2019 | 4 | 0.710 |
Why?
|
| Receptors, Immunologic | 1 | 2021 | 309 | 0.710 |
Why?
|
| Dasatinib | 10 | 2022 | 862 | 0.700 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 7 | 2022 | 505 | 0.690 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2019 | 58 | 0.690 |
Why?
|
| Autoimmune Diseases | 2 | 2020 | 402 | 0.680 |
Why?
|
| Peptidomimetics | 1 | 2019 | 26 | 0.680 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 278 | 0.680 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2020 | 2359 | 0.680 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2019 | 46 | 0.680 |
Why?
|
| Central Nervous System | 1 | 2021 | 436 | 0.680 |
Why?
|
| Pyridazines | 6 | 2023 | 293 | 0.670 |
Why?
|
| Adolescent | 41 | 2024 | 31252 | 0.640 |
Why?
|
| Blast Crisis | 6 | 2021 | 557 | 0.640 |
Why?
|
| Clonal Evolution | 4 | 2021 | 253 | 0.630 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 158 | 0.630 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 4 | 2021 | 114 | 0.630 |
Why?
|
| Neoplasm, Residual | 9 | 2023 | 1656 | 0.620 |
Why?
|
| Janus Kinases | 2 | 2019 | 174 | 0.620 |
Why?
|
| Immunologic Factors | 2 | 2019 | 649 | 0.620 |
Why?
|
| Survival Rate | 31 | 2022 | 12221 | 0.620 |
Why?
|
| Disease Management | 7 | 2020 | 1052 | 0.620 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2017 | 118 | 0.590 |
Why?
|
| Mycoses | 2 | 2021 | 386 | 0.580 |
Why?
|
| Age Factors | 11 | 2021 | 5377 | 0.570 |
Why?
|
| Thiazoles | 4 | 2021 | 726 | 0.570 |
Why?
|
| Scedosporium | 1 | 2016 | 23 | 0.570 |
Why?
|
| Mitochondrial Proteins | 1 | 2019 | 369 | 0.570 |
Why?
|
| Gastroenteritis | 1 | 2019 | 300 | 0.570 |
Why?
|
| Thrombocytosis | 3 | 2023 | 121 | 0.570 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 1073 | 0.570 |
Why?
|
| Saccharomycetales | 1 | 2016 | 44 | 0.560 |
Why?
|
| Cladribine | 7 | 2023 | 233 | 0.560 |
Why?
|
| Aniline Compounds | 3 | 2022 | 177 | 0.560 |
Why?
|
| Medicine in Literature | 1 | 2015 | 5 | 0.560 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2015 | 310 | 0.550 |
Why?
|
| Disease-Free Survival | 31 | 2022 | 10001 | 0.550 |
Why?
|
| Lymphadenopathy | 1 | 2017 | 90 | 0.550 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2019 | 621 | 0.550 |
Why?
|
| Retrospective Studies | 43 | 2024 | 37905 | 0.540 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2015 | 33 | 0.540 |
Why?
|
| Arabinonucleosides | 6 | 2020 | 437 | 0.530 |
Why?
|
| Trust | 1 | 2015 | 99 | 0.510 |
Why?
|
| Pancreatitis | 1 | 2017 | 267 | 0.510 |
Why?
|
| Megakaryocytes | 1 | 2015 | 104 | 0.500 |
Why?
|
| Neoplasm Proteins | 9 | 2020 | 3230 | 0.500 |
Why?
|
| Nuclear Proteins | 8 | 2023 | 3343 | 0.500 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 833 | 0.500 |
Why?
|
| Geotrichum | 1 | 2014 | 6 | 0.490 |
Why?
|
| Geotrichosis | 1 | 2014 | 6 | 0.490 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 1688 | 0.490 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2016 | 2488 | 0.490 |
Why?
|
| Induction Chemotherapy | 9 | 2022 | 669 | 0.470 |
Why?
|
| Janus Kinase 1 | 1 | 2014 | 121 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2024 | 10035 | 0.470 |
Why?
|
| Biomedical Research | 1 | 2021 | 806 | 0.460 |
Why?
|
| Isocitrate Dehydrogenase | 5 | 2023 | 480 | 0.460 |
Why?
|
| Survival Analysis | 22 | 2021 | 9180 | 0.460 |
Why?
|
| Biomarkers, Tumor | 11 | 2021 | 10331 | 0.450 |
Why?
|
| Anemia | 6 | 2023 | 689 | 0.450 |
Why?
|
| Vidarabine | 9 | 2022 | 1341 | 0.450 |
Why?
|
| Stem Cell Transplantation | 6 | 2022 | 1360 | 0.450 |
Why?
|
| Imidazoles | 6 | 2023 | 999 | 0.430 |
Why?
|
| Fusion Proteins, bcr-abl | 7 | 2023 | 1094 | 0.420 |
Why?
|
| Doxorubicin | 9 | 2023 | 3005 | 0.420 |
Why?
|
| Flow Cytometry | 3 | 2021 | 3033 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2021 | 6207 | 0.420 |
Why?
|
| Daunorubicin | 4 | 2023 | 301 | 0.410 |
Why?
|
| Combined Modality Therapy | 9 | 2023 | 8865 | 0.410 |
Why?
|
| Phenotype | 3 | 2023 | 6295 | 0.410 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 181 | 0.400 |
Why?
|
| Tandem Repeat Sequences | 4 | 2020 | 201 | 0.400 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2020 | 305 | 0.400 |
Why?
|
| Sarcoma, Myeloid | 3 | 2021 | 95 | 0.390 |
Why?
|
| Clinical Trials as Topic | 7 | 2022 | 3719 | 0.390 |
Why?
|
| Adenine Nucleotides | 4 | 2017 | 351 | 0.390 |
Why?
|
| Vincristine | 9 | 2023 | 1511 | 0.380 |
Why?
|
| Disease Progression | 7 | 2022 | 6682 | 0.380 |
Why?
|
| Chromosome Aberrations | 7 | 2018 | 1960 | 0.380 |
Why?
|
| Follow-Up Studies | 26 | 2023 | 14889 | 0.370 |
Why?
|
| Positron-Emission Tomography | 3 | 2017 | 2173 | 0.370 |
Why?
|
| Lymphoma | 1 | 2019 | 1467 | 0.370 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2023 | 3552 | 0.360 |
Why?
|
| Medical Oncology | 2 | 2019 | 1423 | 0.350 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 792 | 0.350 |
Why?
|
| Cyclophosphamide | 10 | 2023 | 3001 | 0.350 |
Why?
|
| Propensity Score | 7 | 2022 | 750 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2023 | 5178 | 0.340 |
Why?
|
| Core Binding Factors | 4 | 2022 | 112 | 0.340 |
Why?
|
| Health Information Exchange | 3 | 2016 | 15 | 0.330 |
Why?
|
| Prospective Studies | 18 | 2022 | 12873 | 0.330 |
Why?
|
| Immunotherapy | 2 | 2022 | 3341 | 0.320 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2008 | 24 | 0.320 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2008 | 39 | 0.320 |
Why?
|
| Child | 10 | 2023 | 29154 | 0.310 |
Why?
|
| Quinuclidines | 1 | 2008 | 48 | 0.310 |
Why?
|
| Multiple Myeloma | 2 | 2021 | 2138 | 0.310 |
Why?
|
| Muscarinic Antagonists | 1 | 2008 | 83 | 0.300 |
Why?
|
| Salvage Therapy | 5 | 2019 | 2054 | 0.300 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2020 | 755 | 0.300 |
Why?
|
| Immunophenotyping | 8 | 2021 | 1681 | 0.290 |
Why?
|
| Alleles | 5 | 2020 | 2437 | 0.290 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1331 | 0.290 |
Why?
|
| Glioblastoma | 1 | 2017 | 1797 | 0.290 |
Why?
|
| Transcription Factors | 6 | 2023 | 5270 | 0.280 |
Why?
|
| RNA-Binding Proteins | 3 | 2023 | 984 | 0.280 |
Why?
|
| Piperazines | 2 | 2013 | 2101 | 0.280 |
Why?
|
| Peptides | 2 | 2024 | 1479 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2018 | 317 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2022 | 3251 | 0.280 |
Why?
|
| Celiac Disease | 1 | 2007 | 75 | 0.280 |
Why?
|
| Drug Administration Schedule | 9 | 2020 | 3472 | 0.280 |
Why?
|
| Polycythemia | 2 | 2024 | 49 | 0.280 |
Why?
|
| Information Dissemination | 2 | 2020 | 272 | 0.280 |
Why?
|
| Apoptosis | 7 | 2023 | 7591 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 5 | 2024 | 4367 | 0.270 |
Why?
|
| Febrile Neutropenia | 2 | 2024 | 65 | 0.270 |
Why?
|
| Interleukin-3 | 2 | 2023 | 96 | 0.270 |
Why?
|
| Bortezomib | 2 | 2017 | 543 | 0.270 |
Why?
|
| Cytokines | 3 | 2022 | 2809 | 0.260 |
Why?
|
| Translocation, Genetic | 5 | 2023 | 1245 | 0.260 |
Why?
|
| Cell Cycle Proteins | 3 | 2023 | 2045 | 0.260 |
Why?
|
| Animals | 15 | 2023 | 59536 | 0.260 |
Why?
|
| Karyotype | 7 | 2022 | 234 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2020 | 4938 | 0.260 |
Why?
|
| Maintenance Chemotherapy | 3 | 2021 | 202 | 0.250 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2007 | 128 | 0.250 |
Why?
|
| Risk | 4 | 2020 | 1972 | 0.250 |
Why?
|
| Hematopoiesis | 2 | 2022 | 560 | 0.250 |
Why?
|
| Intestine, Small | 1 | 2008 | 499 | 0.250 |
Why?
|
| Dexamethasone | 9 | 2023 | 1450 | 0.240 |
Why?
|
| Polyethylene Glycols | 2 | 2018 | 615 | 0.240 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2022 | 665 | 0.240 |
Why?
|
| Hepcidins | 1 | 2024 | 34 | 0.240 |
Why?
|
| Chromosome Inversion | 2 | 2023 | 182 | 0.240 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 560 | 0.230 |
Why?
|
| Internet | 3 | 2016 | 706 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2022 | 1242 | 0.230 |
Why?
|
| Time Factors | 7 | 2020 | 12926 | 0.230 |
Why?
|
| Biology | 1 | 2023 | 75 | 0.230 |
Why?
|
| Imatinib Mesylate | 4 | 2019 | 1665 | 0.230 |
Why?
|
| Transplantation, Homologous | 4 | 2021 | 2843 | 0.230 |
Why?
|
| Retinoic Acid Receptor alpha | 2 | 2020 | 95 | 0.220 |
Why?
|
| Child, Preschool | 6 | 2021 | 16273 | 0.220 |
Why?
|
| Thalidomide | 3 | 2015 | 569 | 0.220 |
Why?
|
| Tretinoin | 3 | 2021 | 623 | 0.220 |
Why?
|
| Nucleosides | 1 | 2022 | 60 | 0.220 |
Why?
|
| Cohort Studies | 9 | 2022 | 9244 | 0.220 |
Why?
|
| Biomarkers | 8 | 2022 | 5047 | 0.210 |
Why?
|
| North America | 1 | 2023 | 314 | 0.210 |
Why?
|
| Oxazoles | 1 | 2022 | 60 | 0.210 |
Why?
|
| Lymph Nodes | 3 | 2020 | 2967 | 0.210 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2023 | 122 | 0.210 |
Why?
|
| Staurosporine | 3 | 2019 | 143 | 0.200 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2023 | 275 | 0.200 |
Why?
|
| Erythropoietin | 1 | 2023 | 205 | 0.200 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2020 | 217 | 0.200 |
Why?
|
| Standard of Care | 1 | 2023 | 243 | 0.200 |
Why?
|
| Ribonucleoproteins | 1 | 2021 | 123 | 0.200 |
Why?
|
| Fibrosis | 2 | 2022 | 793 | 0.200 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2022 | 749 | 0.190 |
Why?
|
| Graft vs Host Disease | 2 | 2022 | 2638 | 0.190 |
Why?
|
| STAT Transcription Factors | 1 | 2021 | 79 | 0.190 |
Why?
|
| Enzyme Inhibitors | 3 | 2020 | 1879 | 0.190 |
Why?
|
| Signal Transduction | 4 | 2021 | 11965 | 0.190 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2020 | 55 | 0.190 |
Why?
|
| Anemia, Sideroblastic | 1 | 2021 | 58 | 0.190 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 173 | 0.190 |
Why?
|
| Antigen Presentation | 1 | 2021 | 272 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 4849 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 1249 | 0.190 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2021 | 118 | 0.190 |
Why?
|
| Antifungal Agents | 5 | 2021 | 834 | 0.190 |
Why?
|
| Attitude to Computers | 1 | 2020 | 71 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 59 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 247 | 0.180 |
Why?
|
| Thrombocytopenia | 3 | 2021 | 846 | 0.180 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2020 | 83 | 0.180 |
Why?
|
| Rhabdomyolysis | 1 | 2020 | 52 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2022 | 6869 | 0.180 |
Why?
|
| Pathologists | 1 | 2020 | 91 | 0.180 |
Why?
|
| Histone Demethylases | 1 | 2021 | 144 | 0.180 |
Why?
|
| Proteins | 2 | 2019 | 1963 | 0.180 |
Why?
|
| Pilot Projects | 4 | 2020 | 2803 | 0.180 |
Why?
|
| Piperidines | 4 | 2021 | 1035 | 0.180 |
Why?
|
| Transcription Factor 4 | 1 | 2019 | 36 | 0.180 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2019 | 51 | 0.180 |
Why?
|
| International Cooperation | 1 | 2021 | 323 | 0.180 |
Why?
|
| Capillary Leak Syndrome | 1 | 2019 | 14 | 0.180 |
Why?
|
| United States | 4 | 2022 | 15433 | 0.180 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2019 | 43 | 0.170 |
Why?
|
| Sulfones | 1 | 2020 | 143 | 0.170 |
Why?
|
| Protein Domains | 1 | 2020 | 314 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2021 | 280 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1664 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2020 | 311 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 2195 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2022 | 604 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 598 | 0.170 |
Why?
|
| Calreticulin | 2 | 2018 | 74 | 0.170 |
Why?
|
| Benzothiazoles | 2 | 2021 | 94 | 0.170 |
Why?
|
| Mentors | 1 | 2021 | 203 | 0.170 |
Why?
|
| Receptors, CXCR4 | 1 | 2020 | 269 | 0.170 |
Why?
|
| Methotrexate | 3 | 2017 | 999 | 0.160 |
Why?
|
| Transcriptome | 3 | 2023 | 1859 | 0.160 |
Why?
|
| Erythrocytes | 2 | 2023 | 339 | 0.160 |
Why?
|
| Diploidy | 1 | 2018 | 114 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 161 | 0.160 |
Why?
|
| Diagnosis, Differential | 7 | 2023 | 4744 | 0.160 |
Why?
|
| Patient Dropouts | 1 | 2019 | 88 | 0.160 |
Why?
|
| Serine-Arginine Splicing Factors | 3 | 2023 | 88 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2023 | 2232 | 0.160 |
Why?
|
| Drug Design | 1 | 2020 | 375 | 0.160 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2018 | 24 | 0.160 |
Why?
|
| Pyridines | 2 | 2022 | 1244 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 2 | 2019 | 1443 | 0.160 |
Why?
|
| Precision Medicine | 2 | 2023 | 1154 | 0.160 |
Why?
|
| Pyrroles | 1 | 2022 | 576 | 0.160 |
Why?
|
| Adenine | 4 | 2023 | 631 | 0.160 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2018 | 52 | 0.160 |
Why?
|
| Rituximab | 4 | 2017 | 1528 | 0.160 |
Why?
|
| Glycine | 1 | 2020 | 289 | 0.160 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 475 | 0.160 |
Why?
|
| Quinolines | 1 | 2021 | 383 | 0.160 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 2864 | 0.160 |
Why?
|
| Hyperbilirubinemia | 1 | 2018 | 78 | 0.160 |
Why?
|
| Benzoates | 1 | 2019 | 136 | 0.160 |
Why?
|
| Vitamin B Complex | 1 | 2018 | 51 | 0.160 |
Why?
|
| Epigenesis, Genetic | 3 | 2023 | 1399 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 600 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 11538 | 0.150 |
Why?
|
| Cytogenetic Analysis | 5 | 2019 | 568 | 0.150 |
Why?
|
| Carnitine | 1 | 2018 | 94 | 0.150 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2018 | 261 | 0.150 |
Why?
|
| Haptoglobins | 1 | 2017 | 26 | 0.150 |
Why?
|
| Hydroxyurea | 3 | 2023 | 204 | 0.150 |
Why?
|
| Benzamides | 2 | 2013 | 1832 | 0.150 |
Why?
|
| RNA | 1 | 2022 | 1013 | 0.150 |
Why?
|
| Hydrazines | 1 | 2019 | 208 | 0.150 |
Why?
|
| Medicare | 1 | 2022 | 860 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2021 | 2291 | 0.150 |
Why?
|
| Protein Array Analysis | 1 | 2019 | 501 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2016 | 907 | 0.150 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 643 | 0.150 |
Why?
|
| Hydrolases | 1 | 2017 | 123 | 0.150 |
Why?
|
| Drug Industry | 1 | 2017 | 88 | 0.150 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 388 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2017 | 104 | 0.150 |
Why?
|
| RNA Splicing Factors | 3 | 2023 | 153 | 0.140 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 176 | 0.140 |
Why?
|
| Blood Platelets | 2 | 2019 | 731 | 0.140 |
Why?
|
| Education, Medical | 1 | 2020 | 331 | 0.140 |
Why?
|
| Skin | 3 | 2023 | 1259 | 0.140 |
Why?
|
| B-Lymphocytes | 3 | 2023 | 1294 | 0.140 |
Why?
|
| Spinal Cord Diseases | 1 | 2017 | 90 | 0.140 |
Why?
|
| Anemia, Aplastic | 1 | 2017 | 214 | 0.140 |
Why?
|
| Mucor | 1 | 2015 | 18 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 524 | 0.140 |
Why?
|
| Genome, Fungal | 1 | 2015 | 54 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 5539 | 0.130 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2016 | 132 | 0.130 |
Why?
|
| Phenylurea Compounds | 2 | 2021 | 580 | 0.130 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 246 | 0.130 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 280 | 0.130 |
Why?
|
| DNA Methylation | 4 | 2019 | 2669 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 1209 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 2015 | 74 | 0.130 |
Why?
|
| Thymoma | 1 | 2018 | 246 | 0.130 |
Why?
|
| Morpholines | 1 | 2016 | 289 | 0.130 |
Why?
|
| Benzimidazoles | 2 | 2019 | 428 | 0.130 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 1046 | 0.130 |
Why?
|
| Leukemia, B-Cell | 1 | 2016 | 117 | 0.130 |
Why?
|
| Histocytochemistry | 1 | 2015 | 185 | 0.130 |
Why?
|
| Aminopyridines | 1 | 2016 | 212 | 0.130 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 2015 | 111 | 0.130 |
Why?
|
| Fatal Outcome | 2 | 2016 | 829 | 0.130 |
Why?
|
| Erythrocyte Indices | 1 | 2014 | 24 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 544 | 0.130 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2015 | 73 | 0.130 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 482 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 698 | 0.130 |
Why?
|
| Vaccination | 1 | 2021 | 1123 | 0.120 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2014 | 26 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 2315 | 0.120 |
Why?
|
| Sequence Deletion | 2 | 2014 | 875 | 0.120 |
Why?
|
| Stem Cell Niche | 1 | 2015 | 94 | 0.120 |
Why?
|
| Societies, Medical | 2 | 2019 | 1335 | 0.120 |
Why?
|
| Leukocytosis | 1 | 2014 | 112 | 0.120 |
Why?
|
| Leukapheresis | 1 | 2014 | 152 | 0.120 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2014 | 10 | 0.120 |
Why?
|
| Mucormycosis | 1 | 2015 | 108 | 0.120 |
Why?
|
| Plasma Cells | 1 | 2015 | 192 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2015 | 641 | 0.120 |
Why?
|
| Eye Neoplasms | 1 | 2016 | 247 | 0.120 |
Why?
|
| SEER Program | 1 | 2017 | 1000 | 0.120 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 223 | 0.120 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2013 | 13 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2014 | 135 | 0.120 |
Why?
|
| NF-kappa B | 2 | 2017 | 1549 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 400 | 0.120 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2013 | 60 | 0.120 |
Why?
|
| Allografts | 3 | 2022 | 650 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 4298 | 0.110 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2015 | 365 | 0.110 |
Why?
|
| Prodrugs | 1 | 2015 | 217 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2020 | 650 | 0.110 |
Why?
|
| Research | 1 | 2016 | 415 | 0.110 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2014 | 115 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 1248 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 810 | 0.110 |
Why?
|
| Computational Biology | 1 | 2019 | 1271 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2016 | 771 | 0.110 |
Why?
|
| Platelet Count | 3 | 2019 | 490 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2013 | 134 | 0.110 |
Why?
|
| Splicing Factor U2AF | 2 | 2023 | 48 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2014 | 402 | 0.110 |
Why?
|
| Niacinamide | 1 | 2014 | 421 | 0.110 |
Why?
|
| Biopsy | 2 | 2017 | 3443 | 0.100 |
Why?
|
| Hypoxia | 1 | 2015 | 443 | 0.100 |
Why?
|
| Patient Safety | 1 | 2018 | 649 | 0.100 |
Why?
|
| Consolidation Chemotherapy | 3 | 2020 | 155 | 0.100 |
Why?
|
| Gene Expression | 3 | 2018 | 3570 | 0.100 |
Why?
|
| Cytogenetics | 3 | 2020 | 149 | 0.100 |
Why?
|
| Chromosome Banding | 3 | 2017 | 256 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 984 | 0.100 |
Why?
|
| Antigens, CD | 2 | 2013 | 1385 | 0.100 |
Why?
|
| Risk Factors | 7 | 2023 | 17523 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 588 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 1375 | 0.100 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 2283 | 0.100 |
Why?
|
| Cell Line, Tumor | 6 | 2023 | 14551 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 388 | 0.090 |
Why?
|
| Down Syndrome | 1 | 2013 | 226 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 2403 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2015 | 574 | 0.090 |
Why?
|
| Drug Synergism | 3 | 2019 | 1313 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 5159 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 3 | 2021 | 1290 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 5112 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2015 | 691 | 0.090 |
Why?
|
| Probability | 1 | 2012 | 866 | 0.090 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 3869 | 0.090 |
Why?
|
| Aminoglycosides | 2 | 2022 | 220 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2014 | 674 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 503 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2016 | 6150 | 0.080 |
Why?
|
| Interferon-alpha | 2 | 2023 | 889 | 0.080 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2019 | 65 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 4988 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 5687 | 0.080 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1742 | 0.080 |
Why?
|
| Solifenacin Succinate | 1 | 2008 | 3 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 1914 | 0.080 |
Why?
|
| Tomography, X-Ray | 1 | 2008 | 13 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2015 | 945 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 4549 | 0.080 |
Why?
|
| Pyridones | 2 | 2022 | 348 | 0.080 |
Why?
|
| Mice | 7 | 2023 | 34495 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2015 | 2218 | 0.080 |
Why?
|
| Glutens | 1 | 2007 | 9 | 0.080 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2008 | 37 | 0.080 |
Why?
|
| Drug Evaluation | 2 | 2020 | 425 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2013 | 1039 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 860 | 0.070 |
Why?
|
| Pentostatin | 2 | 2019 | 119 | 0.070 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 486 | 0.070 |
Why?
|
| Safety | 2 | 2018 | 465 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2007 | 118 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 4320 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2015 | 2022 | 0.070 |
Why?
|
| Duodenum | 1 | 2007 | 149 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2013 | 1824 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 7548 | 0.070 |
Why?
|
| Bilirubin | 2 | 2018 | 221 | 0.070 |
Why?
|
| Sex Factors | 3 | 2017 | 2139 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2018 | 684 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 3821 | 0.060 |
Why?
|
| Hematologic Agents | 1 | 2024 | 13 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2010 | 1152 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2012 | 1756 | 0.060 |
Why?
|
| Hematocrit | 1 | 2024 | 142 | 0.060 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2023 | 52 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 672 | 0.060 |
Why?
|
| Karyotyping | 2 | 2017 | 1022 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2023 | 202 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2023 | 196 | 0.060 |
Why?
|
| Injections | 1 | 2024 | 285 | 0.060 |
Why?
|
| Phlebotomy | 1 | 2023 | 26 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 1363 | 0.050 |
Why?
|
| Neutropenia | 2 | 2019 | 968 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2020 | 1163 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 864 | 0.050 |
Why?
|
| Patient Selection | 2 | 2021 | 2055 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2023 | 253 | 0.050 |
Why?
|
| Gender Identity | 1 | 2021 | 75 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2021 | 155 | 0.050 |
Why?
|
| Chimerism | 1 | 2021 | 63 | 0.050 |
Why?
|
| Cellular Senescence | 1 | 2023 | 382 | 0.050 |
Why?
|
| Azoles | 1 | 2021 | 47 | 0.050 |
Why?
|
| Indoles | 2 | 2019 | 1009 | 0.050 |
Why?
|
| Prevalence | 2 | 2019 | 3260 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 2483 | 0.050 |
Why?
|
| Iron | 1 | 2024 | 376 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2022 | 314 | 0.050 |
Why?
|
| IMP Dehydrogenase | 1 | 2020 | 27 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 371 | 0.050 |
Why?
|
| Genomics | 2 | 2022 | 2738 | 0.050 |
Why?
|
| Survivorship | 1 | 2020 | 109 | 0.050 |
Why?
|
| Genes, ras | 1 | 2022 | 667 | 0.040 |
Why?
|
| Mastocytosis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 266 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 4892 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2023 | 612 | 0.040 |
Why?
|
| Cell Survival | 2 | 2016 | 3045 | 0.040 |
Why?
|
| ras Proteins | 1 | 2022 | 770 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2021 | 837 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2024 | 2588 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 332 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 29 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2019 | 223 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2018 | 104 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 397 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 452 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2017 | 82 | 0.040 |
Why?
|
| Antigens, Neoplasm | 2 | 2015 | 1506 | 0.040 |
Why?
|
| Platelet Transfusion | 1 | 2018 | 156 | 0.040 |
Why?
|
| Subacute Combined Degeneration | 1 | 2017 | 16 | 0.040 |
Why?
|
| Naphthyridines | 1 | 2017 | 41 | 0.040 |
Why?
|
| World Health Organization | 1 | 2018 | 316 | 0.040 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 44 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 409 | 0.040 |
Why?
|
| Antilymphocyte Serum | 1 | 2017 | 228 | 0.040 |
Why?
|
| Triazoles | 1 | 2021 | 617 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2022 | 1152 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2020 | 943 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2017 | 257 | 0.040 |
Why?
|
| Stem Cells | 1 | 2023 | 1213 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2023 | 1048 | 0.040 |
Why?
|
| Homocysteine | 1 | 2017 | 138 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 275 | 0.030 |
Why?
|
| Biodiversity | 1 | 2016 | 91 | 0.030 |
Why?
|
| Onychomycosis | 1 | 2015 | 17 | 0.030 |
Why?
|
| Proteomics | 1 | 2023 | 1380 | 0.030 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2015 | 31 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2016 | 225 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 173 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2016 | 214 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 106 | 0.030 |
Why?
|
| Metagenomics | 1 | 2016 | 115 | 0.030 |
Why?
|
| Itraconazole | 1 | 2015 | 77 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 192 | 0.030 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2015 | 36 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 2015 | 44 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2022 | 1230 | 0.030 |
Why?
|
| Fungemia | 1 | 2015 | 116 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 1544 | 0.030 |
Why?
|
| Metagenome | 1 | 2016 | 176 | 0.030 |
Why?
|
| Genes, myc | 1 | 2016 | 358 | 0.030 |
Why?
|
| Enterocolitis | 1 | 2015 | 43 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 269 | 0.030 |
Why?
|
| Infant | 2 | 2022 | 13310 | 0.030 |
Why?
|
| Transaminases | 1 | 2014 | 76 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1819 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 7222 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2015 | 254 | 0.030 |
Why?
|
| Thioguanine | 1 | 2014 | 68 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 657 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 257 | 0.030 |
Why?
|
| Binding Sites | 1 | 2019 | 2171 | 0.030 |
Why?
|
| Nitroimidazoles | 1 | 2015 | 100 | 0.030 |
Why?
|
| Folic Acid | 1 | 2017 | 349 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 1022 | 0.030 |
Why?
|
| Mercaptopurine | 1 | 2014 | 130 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2015 | 289 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 2014 | 81 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 490 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 660 | 0.030 |
Why?
|
| Monosomy | 1 | 2014 | 95 | 0.030 |
Why?
|
| Caspases | 1 | 2016 | 661 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2017 | 583 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2014 | 117 | 0.030 |
Why?
|
| Oxides | 1 | 2014 | 211 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 206 | 0.030 |
Why?
|
| Arsenicals | 1 | 2014 | 201 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 259 | 0.030 |
Why?
|
| Neutrophils | 1 | 2018 | 835 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 327 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2013 | 141 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2017 | 1090 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 676 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 314 | 0.030 |
Why?
|
| Critical Illness | 1 | 2018 | 714 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 884 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 376 | 0.030 |
Why?
|
| Trisomy | 1 | 2014 | 231 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 1085 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2021 | 2238 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2352 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 1910 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2016 | 7226 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 3438 | 0.030 |
Why?
|
| Fatigue | 1 | 2018 | 1239 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 719 | 0.030 |
Why?
|
| Nausea | 1 | 2013 | 525 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2013 | 256 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 2307 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2013 | 421 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Point Mutation | 1 | 2013 | 769 | 0.020 |
Why?
|
| Aging | 1 | 2019 | 1582 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 7702 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1678 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 726 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 3441 | 0.020 |
Why?
|
| Inflammation | 1 | 2019 | 2522 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 6009 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 4804 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2017 | 929 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 3639 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 2927 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 4917 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7573 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 2594 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1283 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6311 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 2961 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8873 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 4975 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 5673 | 0.010 |
Why?
|
| Quality of Life | 1 | 2016 | 4532 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 13658 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 7551 | 0.010 |
Why?
|